|
| Exchange Disseminated Time 16/05/2018 16:27:17 | Glenmark Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors will be held on May 29, 2018, inter alia, to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the year ended March 31, 2018 and to consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2018.
Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from April 01, 2018 to May 31, 2018 (both days inclusive) for the purpose of approval of Standalone and Consolidated Audited Financial Results for the year ended March 31, 2018. |
|
|